Spotlight On: Rituxan® (Rituximab) / Truxima® (Rituximab-Abbs) / Ruxience® (Rituximab-Pvvr) / Riabni™ (Rituximab-Arrx) - April 2026

Why It Matters

Patent challenges directly affect rituximab’s market exclusivity, influencing biosimilar launch timing and pricing dynamics for a multi‑billion‑dollar oncology portfolio.

Key Takeaways

• Several IPRs target core rituximab patents at the USPTO
• Court lawsuits often mirror the same patent claims as IPRs
• Duplicate counting inflates total challenged claim numbers across proceedings
• Patent uncertainty could postpone biosimilar market entry and pricing benefits

Pulse Analysis

Rituximab, the first FDA‑approved monoclonal antibody for non‑Hodgkin lymphoma, remains a cornerstone of oncology therapy, generating over $10 billion in annual global sales. The drug’s commercial success spurred a wave of biosimilars—Truxima®, Ruxience®, and Riabni™—each seeking to capture market share once patent protections erode. However, the pathway to broader adoption is increasingly shaped by the intensity of patent litigation and Inter‑Partes Review (IPR) actions, which can extend exclusivity periods and affect pricing strategies for hospitals and insurers.

The Venable LLP briefing clarifies how claims are counted in these disputes: a single patent claim is recorded once per IPR, regardless of whether it is challenged under § 102, § 103, or both, and once per lawsuit. When the same claim appears in multiple IPRs or separate lawsuits, it is tallied repeatedly, inflating the apparent volume of contested claims. This methodology reveals a dense web of overlapping challenges, underscoring the strategic importance of coordinated legal defenses and the potential for claim‑splitting tactics that can stretch the litigation timeline.

For industry stakeholders, the practical impact is clear. Ongoing uncertainty around rituximab patents can delay biosimilar rollouts, limiting cost‑saving opportunities for payers and patients. Moreover, prolonged disputes may deter investment in next‑generation antibody platforms if the risk of entrenched patent thickets appears high. Companies navigating this landscape must balance aggressive patent enforcement with collaborative settlement approaches to ensure timely market entry while preserving revenue streams.